

## **OP27.2**

### **Cost effectiveness considerations concerning Incretins in diabetes type 2**

*Michael Craftman(1), K Vaegter(2), N Pihlström(3), D Jansson(4)*

*(1) Michael Craftman, Riverside Primary Health Care Center, Nyköping, Sweden*

*(2) Keld Vaegter, Riverside Primary Health Care Center, Nyköping, Sweden*

*(3) Nicklas Pihlström, Centre for Clinical Research Sörmland, Sweden*

*(4) Dick Jansson, Riverside Primary Health Care Center, Nyköping, Sweden*

*Corresponding author: Dr Michael Craftman, VC Åsidan, Landstinget Sörmland, Nyköping, Sweden. E-mail: michael.craftman@dll.se*

Diabetes type 2 is an increasing health problem worldwide and the costs a growing challenge. Estimates from WHO anticipates a rise in the prevalence of diabetes type 2 to 7,7% corresponding to 439 million persons in the year 2030. The Swedish National Board of Health recommends HbA1c (glycated hemoglobin) to be lower than 52 mmol/mol.

Our project, initiated by The Drug Committee of Sörmland County, was to evaluate the effect of incretins on HbA1c and estimate the cost of reducing HbA1c to the recommended level at the Riverside Health Care Center, Nyköping, Sweden.

**Method:** All patients treated with incretins during the period 1.1.2014-31.3.2015 were identified and extracted from the medical records data base of Sörmland County. A total of 63 patients were included. The following parameters were evaluated at the onset of the study and at the end: Age, weight, HbA1C substance, dose and price.

**Results:** Incretins showed to be effective in lowering HbA1c, mean reduction -10,0 mmol/mol ( $p < 0,001$ ). The number of patients reaching the HbA1c goal increased from 7 of 63 (11%) at the onset of the study period to 24 of 63 (38%) at the end. No significant weight reduction was observed. Age, gender and choice of incretin had no significant effect on the outcome. The drug cost related to incretin treatment was approximately 710.000 SEK.

**Conclusions:** Incretins showed to be effective drugs in reducing HbA1c in diabetic type 2 patients. At present, incretins are not on the Recommended Drugs list in Sörmland County. The cost/Defined Daily Dose, however, is still significantly higher compared to traditional anti-diabetic drugs. The Drug Committee of Sörmland County will have to take this in consideration when deciding on future anti-diabetic drug treatment strategy.